Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy

Annals of Neurology

Volumn 43, Issue 4, 1998, Pages 446-451

  Isojärvi, Jouko I T ^a   Rättyä, Johanna ^a   Myllylä, Vilho V ^a   Knip, Mikael ^a   Koivunen, Riitta ^a   Pakarinen, Arto J ^b   Tekay, Aydin ^a   Tapanainen, Juha S ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMOTRIGINE; TESTOSTERONE; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; LIPID BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANTICONVULSANTS; CHOLESTEROL, HDL; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN; MENSTRUAL CYCLE; OVARY; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT; TIME FACTORS; TRIAZINES; VALPROIC ACID;

EID: 0031749077     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430406     Document Type: Article

References (26)

1. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388
2. Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584
3. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69
4. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-581
5. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine in the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:756-771
6. Wild RA. Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol 1994;12:38-44
7. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
8. Conway GS, Jacobs HS. Clinical implications of hyperinsulinemia in women. Clin Endocrinol 1993;39:623-632
9. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-372
10. Wolf P. Juvenile myoclonic epilepsy. In: Roger J, Bureau M, Dravet C, et al, eds. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey, 1992:313-327
11. Leach JP, Brodie MJ. Lamotrigine: clinical use. In: Levy R, Dreifuss FE, Mattson RE, et al., eds. Antiepileptic drugs. New York: Raven Press, 1995:889-895
12. Brodie MJ, Richens A, Yuen AWC, for UK Lamotrigine/ Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479
13. Adams J, Poison DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986;293:355-358
14. Andersen L, Dinesen B, Jørgensen PN, et al. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-582
15. 2+/dextran sulfate in its enzymatic measurement. Clin Chem 1978;24:931-933
16. Ponchaut S, Veitch K. Valproate and mitochondria. Biochem Pharmacol 1993;46:199-204
17. Gidal BE, Anderson GD, Spencer NW, et al. Valproic acid (VPA) associated weight gain in monotherapy patients with epilepsy. Epilepsia 1994;35:S142
18. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194
19. Moller DE, Flier JS. Insulin resistance - mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-948
20. Han TS, van Leer, Seidell JC, Lean MEJ. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995;311:1401-1405
21. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37:119-126
22. Wild RA, Van Nort JJ, Grubb B, et al. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990;54:255-259
23. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333: 853-861
24. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged med with dyslipidemia. N Engl J Med 1987;317:1237-1245
25. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346
26. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-619